Jadvar H, et al. - A total of 76 men with metastatic castration-sensitive prostate cancer enrolled from 2005 to 2011 underwent ¹⁸F-FDG PET/CT and were followed prospectively for time to hormonal treatment failure (THTF), defined as treatment shift to chemotherapy or death in order to evaluate the relationship of ¹⁸F-FDG PET/CT with THTF in men with metastatic castration-sensitive prostate cancer. Forty-three people had hormonal treatment failure, and eight died without documented treatment failure. Sum of SUV_max and number of lesions determined from ¹⁸F-FDG PET/CT give independent prognostic data on THTF in men with metastatic castration-sensitive prostate cancer.